Search research articles
Contact Us
Filters
Showing results (41-50 of 89) with videos related to
Page
of 9
Sort By:
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
August 1, 1991
Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection
A S Abi-Aad, R A Figlin, A Belldegrun, et al.
Cellular Immunology
|
November 1, 1988
Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a)
O Martínez-Maza, R A Figlin, J V Giorgi, et al.
Current Urology Reports
|
June 27, 2002
Dendritic cell-based immunotherapy of renal cell carcinoma
B J Gitlitz, R A Figlin, A J Pantuck, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1987
Application of a new method for detecting the phenotype of target binding cells
R A Lindemann, J A Jenkins, R A Figlin, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for non-small cell lung cancer
R Cameron, J Fringer, C Taylor, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for prostate cancer
T Ahlering, R Parker, S Kumar, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
December 1, 1991
Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha
E L Jacobs, M J Clare-Salzler, I J Chopra, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for colorectal cancer
A Venook, J Goodnight, S Kumar, et al.
Journal of Biological Response Modifiers
|
February 1, 1989
Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results
G P Sarna, R A Figlin, M Pertcheck, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for small cell lung cancer
R Cameron, N G Smith, C Taylor, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 89) with videos related to
Sort By:
Page
of 9
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
August 1, 1991
Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection
A S Abi-Aad, R A Figlin, A Belldegrun, et al.
Cellular Immunology
|
November 1, 1988
Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a)
O Martínez-Maza, R A Figlin, J V Giorgi, et al.
Current Urology Reports
|
June 27, 2002
Dendritic cell-based immunotherapy of renal cell carcinoma
B J Gitlitz, R A Figlin, A J Pantuck, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1987
Application of a new method for detecting the phenotype of target binding cells
R A Lindemann, J A Jenkins, R A Figlin, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for non-small cell lung cancer
R Cameron, J Fringer, C Taylor, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for prostate cancer
T Ahlering, R Parker, S Kumar, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
December 1, 1991
Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha
E L Jacobs, M J Clare-Salzler, I J Chopra, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for colorectal cancer
A Venook, J Goodnight, S Kumar, et al.
Journal of Biological Response Modifiers
|
February 1, 1989
Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results
G P Sarna, R A Figlin, M Pertcheck, et al.
The Cancer Journal From Scientific American
|
May 1, 1996
Practice guidelines for small cell lung cancer
R Cameron, N G Smith, C Taylor, et al.
Page
of 9